. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2012 Dec 18;22(2):295–307. doi: 10.1158/1055-9965.EPI-12-1122

Table 3.

Multivariate analysis of CXCL13 and other biomarkers related to B cell activation and HIV-associated non-Hodgkin lymphoma risk

	>3 years		1–3 years		0–1 year
	OR^a	95% CI	OR^a	95% CI	OR^a	95% CI

CXCL13	2.68	(1.38–5.26)	1.73	(0.84–3.58)	1.63	(0.71–3.82)
sCD30	1.00	(0.40–2.54)	1.58	(0.67–3.78)	2.50	(0.76–8.24)
sCD27	0.39	(0.10–1.51)	0.70	(0.22–2.35)	0.29	(0.07–1.34)
IL6	1.88	(1.17–3.03)	0.94	(0.52–1.74)	1.64	(0.85–3.22)
TNFα	1.62	(0.98–2.69)	1.54	(0.84–2.83)	1.29	(0.80–2.11)
IL10	1.09	(0.86–1.38)	1.27	(0.95–1.71)	1.38	(0.94–2.05)
Neopterin	1.47	(0.50–4.40)	2.41	(0.83–7.03)	5.18	(1.36–19.8)
IP10	1.14	(0.55–2.39)	1.28	(0.61–2.70)	1.73	(0.72–4.18)

OR indicates odds ratio; CI, confidence interval

The ORs represent risk of AIDS-NHL associated with one unit increase in the log transformed biomarker. ORs are adjusted for age at AIDS-NHL diagnosis in cases or reference date in controls, absolute CD4⁺ T cell counts from each visit where the biomarkers were measured, log_e HIV viral RNA levels at set point, and having an AIDS diagnosis prior to AIDS-NHL diagnosis or reference date, and having exposure to HAART prior to AIDS-NHL diagnosis or reference date